{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:13:52Z","timestamp":1791285232139,"version":"4.1.0"},"reference-count":37,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"Italian Ministry of University and Research","award":["2010JS3PMZ"],"award-info":[{"award-number":["2010JS3PMZ"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg\/day) or lifestyle counseling. Changes in SAT and VAT levels (determined by abdominal MRI), insulin sensitivity (according to the Matsuda index), and \u03b2-cell function (\u03b2-index) were assessed during a multiple-sampling oral glucose tolerance test; and circulating levels of IGF-I and IGF-II were assessed before and after a comparable weight loss (7% of initial body weight).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>After comparable weight loss, achieved by 20 patients per arm, and superimposable glycemic control, as reflected by HbA1c level (P = 0.60), reduction in VAT was significantly higher in the liraglutide arm than in the lifestyle arm (P = 0.028), in parallel with a greater improvement in \u03b2-index (P = 0.021). No differences were observed in SAT reduction (P = 0.64). IGF-II serum levels were significantly increased (P = 0.024) only with liraglutide administration, and the increase in IGF-II levels correlated with both a decrease in VAT (\u03c1 = \u22120.435, P = 0.056) and an increase in the \u03b2-index (\u03c1 = 0.55, P = 0.012).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Liraglutide effects on visceral obesity and \u03b2-cell function might provide a rationale for using this molecule in obese subjects in an early phase of glucose metabolism dysregulation natural history.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-0589","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:25:28Z","timestamp":1505435128000},"page":"1556-1564","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":104,"title":["Effects of Liraglutide on Weight Loss, Fat Distribution, and \u03b2-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes"],"prefix":"10.2337","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-905X","authenticated-orcid":false,"given":"Francesca","family":"Santilli","sequence":"first","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola G.","family":"Simeone","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Guagnano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Leo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica T.","family":"Maccarone","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Di Castelnuovo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Mediterraneo, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sborgia","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-1005","authenticated-orcid":false,"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Parma, and Division of Endocrinology, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermanno","family":"Angelucci","sequence":"additional","affiliation":[{"name":"Department of Clinica Medica, \u201cSS. Annunziata\u201d Chieti Hospital, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, \u201cSS. Annunziata\u201d Chieti Hospital, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cianfarani","sequence":"additional","affiliation":[{"name":"Dipartimento Pediatrico Universitario Ospedaliero, \u201cBambino Ges\u00f9\u201d Children's Hospital\u2014Tor Vergata University, Rome, Italy"},{"name":"Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Manzoli","sequence":"additional","affiliation":[{"name":"Department of Medicine Sciences, University of Ferrara, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Dav\u00ec","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tartaro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), \u201cG. d'Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"2022031301503129500_B1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031301503129500_B2","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/eurheartj\/ehv509","article-title":"Obesity and cardiovascular disease: friend or foe","volume":"37","author":"Kim","year":"2016","journal-title":"Eur Heart J"},{"key":"2022031301503129500_B3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/2012.jama.11132","article-title":"Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults","volume":"308","author":"Neeland","year":"2012","journal-title":"JAMA"},{"key":"2022031301503129500_B4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301503129500_B5","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2022031301503129500_B6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab"},{"key":"2022031301503129500_B7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes","volume":"30","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301503129500_B8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/db09-0063","article-title":"Glucagon-like peptide-1 protects \u03b2-cells against apoptosis by increasing the activity of an Igf-2\/Igf-1 receptor autocrine loop","volume":"58","author":"Cornu","year":"2009","journal-title":"Diabetes"},{"key":"2022031301503129500_B9","first-page":"E534","article-title":"IGF-II receptors and IGF-II-stimulated glucose transport in human fat cells","volume":"258","author":"Sinha","year":"1990","journal-title":"Am J Physiol"},{"key":"2022031301503129500_B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301503129500_B11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cjca.2014.12.009","article-title":"Obesity and cardiovascular disease: weight loss is not the only target","volume":"31","author":"Despr\u00e9s","year":"2015","journal-title":"Can J Cardiol"},{"key":"2022031301503129500_B12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301503129500_B13","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"Classification and diagnosis of diabetes","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301503129500_B14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031301503129500_B15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1152\/jappl.1992.72.2.787","article-title":"Quantification of adipose tissue by MRI: relationship with anthropometric variables","volume":"72","author":"Ross","year":"1992","journal-title":"J Appl Physiol (1985)"},{"key":"2022031301503129500_B16","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031301503129500_B17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2362.2001.00827.x","article-title":"Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion","volume":"31","author":"Cretti","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"2022031301503129500_B18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1037\/0022-006X.66.4.641","article-title":"Are smaller weight losses or more achievable weight loss goals better in the long term for obese patients","volume":"66","author":"Jeffery","year":"1998","journal-title":"J Consult Clin Psychol"},{"key":"2022031301503129500_B19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.5858\/1999-123-0763-EOAFAH","article-title":"Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c","volume":"123","author":"Khuu","year":"1999","journal-title":"Arch Pathol Lab Med"},{"key":"2022031301503129500_B20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2014.01.052","article-title":"Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children","volume":"165","author":"Cianfarani","year":"2014","journal-title":"J Pediatr"},{"key":"2022031301503129500_B21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocr J"},{"key":"2022031301503129500_B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","article-title":"Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients","volume":"13","author":"Li","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022031301503129500_B23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00592-014-0710-z","article-title":"Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study","volume":"52","author":"Morano","year":"2015","journal-title":"Acta Diabetol"},{"key":"2022031301503129500_B24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20160803","article-title":"GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction","volume":"131","author":"Pastel","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"2022031301503129500_B25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L","article-title":"Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes","volume":"172","author":"Montrose-Rafizadeh","year":"1997","journal-title":"J Cell Physiol"},{"key":"2022031301503129500_B26","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"key":"2022031301503129500_B27","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1074\/jbc.M111.310342","article-title":"Regulation of adipocyte formation by GLP-1\/GLP-1R signaling","volume":"287","author":"Challa","year":"2012","journal-title":"J Biol Chem"},{"key":"2022031301503129500_B28","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/bph.13481","article-title":"Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes","volume":"173","author":"El Bekay","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2022031301503129500_B29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"2022031301503129500_B30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","article-title":"iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy","volume":"24","author":"Lynch","year":"2016","journal-title":"Cell Metab"},{"key":"2022031301503129500_B31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1210\/jc.2014-2853","article-title":"Relationship between insulin resistance and \u03b2-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes","volume":"100","author":"F\u00e6rch","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301503129500_B32","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.2337\/dc14-0893","article-title":"Liraglutide and the preservation of pancreatic \u03b2-cell function in early type 2 diabetes: the LIBRA trial","volume":"37","author":"Retnakaran","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301503129500_B33","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.2337\/dc14-2418","article-title":"Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic \u03b2-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278","volume":"38","author":"Arnolds","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301503129500_B34","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.2337\/diabetes.53.suppl_3.S26","article-title":"Beta-cell function in obesity: effects of weight loss","volume":"53","author":"Ferrannini","year":"2004","journal-title":"Diabetes"},{"key":"2022031301503129500_B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2016.08.020","article-title":"One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden","volume":"253","author":"Fiorentino","year":"2016","journal-title":"Atherosclerosis"},{"key":"2022031301503129500_B36","doi-asserted-by":"crossref","first-page":"10538","DOI":"10.1074\/jbc.M109.091116","article-title":"Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression","volume":"285","author":"Cornu","year":"2010","journal-title":"J Biol Chem"},{"key":"2022031301503129500_B37","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.2337\/db14-1735","article-title":"Autocrine action of IGF2 regulates adult \u03b2-cell mass and function","volume":"64","author":"Modi","year":"2015","journal-title":"Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-0589","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1556\/551864\/dc170589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1556\/551864\/dc170589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:52:59Z","timestamp":1647150779000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/11\/1556\/36941\/Effects-of-Liraglutide-on-Weight-Loss-Fat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,9,14]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-0589","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}